Argenx Enters Japan With Smooth Approval – How Was It Possible?
Strategy Behind Unusual Move
Belgian bioventure Argenx has made an unusually smooth commercial entry to Japan with Vyvgart almost as fast as the launch of the myasthenia gravis drug in the US. Its founder admits it was a “bold move” for a European pharma company and revealed how the unexpected entrance was made possible.
You may also be interested in...
Will BioMarin be second time lucky with its hemophilia gene therapy Roctavian in the EU? The European Medicines Agency could soon decide whether the product should be approved.
In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.
Patients in the UK with generalized myasthenia gravis are being allowed to receive argenx’s yet-to-be approved drug efgartigimod.